ScholarLens Back to search
2013•Drug and Therapeutics BulletinRequires access

▼Glycopyrronium for COPD

Author information unavailable

Open publisher page 7 citations

Abstract

▾Glycopyrronium powder for inhalation (Seebri Breezhaler-Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).¹ This is the third long-acting agent that has recently been licensed in the UK for use in people with COPD (see ▾Indacaterol for COPD² and ▾Aclidinium for COPD?³). The company's promotional material claims that 'Seebri is a once daily LAMA which supports cost effective prescribing at all stages of COPD'.⁴ In this article we review the evidence for glycopyrronium and assess its place in the management of COPD.

About this research paper

What this paper is about

▾Glycopyrronium powder for inhalation (Seebri Breezhaler-Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).¹ This is the third long-acting agent that has recently been licensed in the UK for use in people with COPD (see ▾Indacaterol for COPD² and ▾Aclidinium for COPD?³). The company's promotional material claims that 'Seebri is a once daily LAMA which supports cost effective prescribing at all stages of COPD'.⁴ In this article we review the evidence for glycopyrronium and assess its place in the management of COPD.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

▾Glycopyrronium powder for inhalation (Seebri Breezhaler-Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).¹ This is the third long-acting agent that has recently been licensed in the UK for use in people with COPD (see ▾Indacaterol for COPD² and ▾Aclidinium for COPD?³). The company's promotional material claims that 'Seebri is a once daily LAMA which supports cost effective prescribing at all stages of COPD'.⁴ In this article we review the evidence for glycopyrronium and assess its place in the management of COPD.

Key concepts: Indacaterol, COPD, Lama, Medicine, Bronchodilator, Muscarinic antagonist, Pulmonary disease, Inhalation

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
▼Glycopyrronium for COPD — Research Paper | ScholarLens